Login Register Cart 0
Generic placeholder image

Current Medical Imaging

Editor-in-Chief

ISSN (Print): 1573-4056
ISSN (Online): 1875-6603

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Is Magnetic Resonance Imaging (MRI) Still a Gold Standard to Detect Breast Cancer: A Meta-analysis

Author(s): Xiaochen Su* and Shaokai Wang

Volume 19, Issue 14, 2023

Published on: 28 March, 2023

Article ID: e060223213475 Pages: 13

DOI: 10.2174/1573405619666230206162504

Price: $65

Abstract

Purpose: Breast cancer is fatal if it is not diagnosed and treated promptly; consequently, early and precise diagnosis is essential. In comparison to mammography and sonography, the sensitivity of MRI to cellular changes and its ability to differentiate benign from malignant tumors make it the preferred imaging technique. Consequently, the present meta-analysis assessed the effectiveness of different imaging modalities for breast cancer detection and evaluated the diagnostic accuracy of MRI.

Methods: Pertinent articles were searched in PubMed, MEDLINE, and Central databases using the appropriate keywords as per the PRISMA guidelines. Retrospective and prospective studies were included according to the predefined PICOS criteria. A meta-analysis was performed using RevMan and MedCalc software, and statistical parameters, such as odds ratio, sensitivity, specificity, likelihood ratios, and accuracy, were calculated. Publication bias was evaluated using Egger’s and Begg’s tests, and diagnostic performance was assessed using Youden’s and Bland-Altman's plots.

Results: Fourteen clinical trials with 4666 breast cancer patients with perineural spread were included. The included studies used MRI for the detection of breast cancer lesions according to the BI-RADS® (Breast Imaging Reporting and Data System) guidelines and stated that it has high sensitivity and diagnostic accuracy. Similarly, the present meta-analysis found a high sensitivity of 86.12 % and a high diagnostic accuracy of 91.2%. Other than this, we obtained a specificity of 65%, a positive likelihood ratio of 2.7, and a negative likelihood ratio of 0.22. The pooled odds ratio (OR) was reported to be 1.87 (95% CI 1.42-2.46), and the pooled risk ratio value was 1.19 (95% CI 1.11-1.28).

Conclusion: Present meta-analysis strongly recommends MRI as an effective imaging method for the detection of breast cancer.

[1]
Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press) 2019; 11: 151-64.
[http://dx.doi.org/10.2147/BCTT.S176070] [PMID: 31040712]
[2]
Ilic L, Haidinger G, Simon J, Hackl M, Schernhammer E, Papantoniou K. Trends in female breast cancer incidence, mortality, and survival in Austria, with focus on age, stage, and birth cohorts (1983–2017). Sci Rep 2022; 12(1): 7048.
[http://dx.doi.org/10.1038/s41598-022-10560-x] [PMID: 35487918]
[3]
Prusty RK, Begum S, Patil A, Naik DD, Pimple S, Mishra G. Knowledge of symptoms and risk factors of breast cancer among women: A community based study in a low socio-economic area of Mumbai, India. BMC Womens Health 2020; 20(1): 106.
[http://dx.doi.org/10.1186/s12905-020-00967-x] [PMID: 32423488]
[4]
Moodley J, Cairncross L, Naiker T, Constant D. From symptom discovery to treatment - women’s pathways to breast cancer care: A cross-sectional study. BMC Cancer 2018; 18(1): 312.
[http://dx.doi.org/10.1186/s12885-018-4219-7] [PMID: 29562894]
[5]
Galipeau N, Klooster B, Krohe M, Tang DH, Revicki DA, Cella D. Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: Qualitative study findings. J Patient Rep Outcomes 2019; 3(1): 10.
[http://dx.doi.org/10.1186/s41687-019-0098-1] [PMID: 30734110]
[6]
Fowler EE, Sellers TA, Lu B, Heine JJ. Breast imaging reporting and data system (BI-RADS) breast composition descriptors: Automated measurement development for full field digital mammography. Med Phys 2013; 40(11): 113502.
[http://dx.doi.org/10.1118/1.4824319] [PMID: 24320473]
[7]
Timmers JMH, van Doorne-Nagtegaal HJ, Zonderland HM, et al. The breast imaging reporting and data system (BI-RADS) in the dutch breast cancer screening programme: Its role as an assessment and stratification tool. Eur Radiol 2012; 22(8): 1717-23.
[http://dx.doi.org/10.1007/s00330-012-2409-2] [PMID: 22415412]
[8]
Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast cancer: Conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer (Auckl) 2015; 9s2(Suppl. 2): BCBCR.S29420.
[http://dx.doi.org/10.4137/BCBCR.S29420] [PMID: 26462242]
[9]
Waks AG, Winer EP. Breast cancer treatment. JAMA 2019; 321(3): 288-300.
[http://dx.doi.org/10.1001/jama.2018.19323] [PMID: 30667505]
[10]
Gardezi SJS, Elazab A, Lei B, Wang T. Breast cancer detection and diagnosis using mammographic data: Systematic review. J Med Internet Res 2019; 21(7): e14464.
[http://dx.doi.org/10.2196/14464] [PMID: 31350843]
[11]
Guo R, Lu G, Qin B, Fei B. Ultrasound imaging technologies for breast cancer detection and management: A review. Ultrasound Med Biol 2018; 44(1): 37-70.
[http://dx.doi.org/10.1016/j.ultrasmedbio.2017.09.012] [PMID: 29107353]
[12]
Dhillon GS, Bell N, Ginat DT, et al. Breast MR imaging: What the radiologist needs to know. J Clin Imaging Sci 2011; 1: 48.
[http://dx.doi.org/10.4103/2156-7514.85655] [PMID: 22059150]
[13]
Yang SK, Cho N, Moon WK. The role of PET/CT for evaluating breast cancer. Korean J Radiol 2007; 8(5): 429-37.
[http://dx.doi.org/10.3348/kjr.2007.8.5.429] [PMID: 17923786]
[14]
Roque R, Cordeiro MR, Armas M, Caramelo F, Caseiro-Alves F, Figueiredo-Dias M. The accuracy of magnetic resonance imaging in predicting the size of pure ductal carcinoma in situ: A systematic review and meta-analysis. NPJ Breast Cancer 2022; 8(1): 77.
[http://dx.doi.org/10.1038/s41523-022-00441-x] [PMID: 35768442]
[15]
Yuan Y, Chen XS, Liu SY, Shen KW. Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: A meta-analysis. In: Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews UK:. 2010.
[16]
Sardanelli F, Giuseppetti GM, Panizza P, et al. Italian Trial for Breast MR in Multifocal/Multicentric Cancer. Sensitivity of MRI versusmammography for detecting foci of multifocal, multicentric breast cancer in Fatty and dense breasts using the whole-breast pathologic examination as a gold standard. AJR Am J Roentgenol 2004; 183(4): 1149-57.
[http://dx.doi.org/10.2214/ajr.183.4.1831149] [PMID: 15385322]
[17]
Shin HJ, Kim HH, Ahn JH, et al. Comparison of mammography, sonography, MRI and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy. Br J Radiol 2011; 84(1003): 612-20.
[http://dx.doi.org/10.1259/bjr/74430952] [PMID: 21081579]
[18]
Gruber IV, Rueckert M, Kagan KO, et al. Measurement of tumour size with mammography, sonography and magnetic resonance imaging as compared to histological tumour size in primary breast cancer. BMC Cancer 2013; 13(1): 328.
[http://dx.doi.org/10.1186/1471-2407-13-328] [PMID: 23826951]
[19]
Pickles MD, Lowry M, Manton DJ, Turnbull LW. Prognostic value of DCE-MRI in breast cancer patients undergoing neoadjuvant chemotherapy: A comparison with traditional survival indicators. Eur Radiol 2015; 25(4): 1097-106.
[http://dx.doi.org/10.1007/s00330-014-3502-5] [PMID: 25424563]
[20]
Proulx F, Correa JA, Ferré R, et al. Value of pre-operative breast MRI for the size assessment of ductal carcinoma in situ. Br J Radiol 2016; 89(1058): 20150543.
[http://dx.doi.org/10.1259/bjr.20150543] [PMID: 26568438]
[21]
Rayzah M, Ryu JM, Lee JE, et al. Preoperative breast magnetic resonance imaging for the assessment of the size of ductal carcinoma in situ. J Breast Dis 2016; 4(2): 77-84.
[http://dx.doi.org/10.14449/jbd.2016.4.2.77]
[22]
Mukherjee SD, Hodgson N, Lovrics PJ, et al. A retrospective study evaluating the impact of preoperative breast MRI on surgical decision- making in young patients (≤50 Years) with invasive breast cancer. Breast Cancer 2016; 10: BCBCR.S38432.
[http://dx.doi.org/10.4137/BCBCR.S38432] [PMID: 27226720]
[23]
Preibsch H, Beckmann J, Pawlowski J, et al. Accuracy of breast magnetic resonance imaging compared to mammography in the preoperative detection and measurement of pure ductal carcinoma in situ: A retrospective analysis. Acad Radiol 2019; 26(6): 760-5.
[http://dx.doi.org/10.1016/j.acra.2018.07.013] [PMID: 30149976]
[24]
Liu H, Zhan H, Sun D, Zhang Y. Comparison of BSGI, MRI, mammography, and ultrasound for the diagnosis of breast lesions and their correlations with specific molecular subtypes in Chinese women. BMC Med Imaging 2020; 20(1): 98.
[http://dx.doi.org/10.1186/s12880-020-00497-w] [PMID: 32799808]
[25]
Osei KV, Mehta AK, Thigpen DM, Rapelyea J, Friedman S, Brem RF. Abbreviated breast MRI for screening high-risk women: Comparison with the full clinical protocol. J Breast Imaging 2021; 3(2): 196-200.
[http://dx.doi.org/10.1093/jbi/wbaa101]
[26]
Wu WP, Chen CY, Lee CW, et al. Impact of pre-operative breast magnetic resonance imaging on contralateral synchronous and metachronous breast cancer detection—A case control comparison study with 1468 primary operable breast cancer patients with mean follow-up of 102 months. PLoS One 2021; 16(11): e0260093.
[http://dx.doi.org/10.1371/journal.pone.0260093] [PMID: 34793522]
[27]
Zhu X, Cao Y, Li R, Zhu M, Chen X. Diagnostic performance of mammography and magnetic resonance imaging for evaluating mammographically visible breast masses. J Int Med Res 2021; 49(9): 300060520973092.
[http://dx.doi.org/10.1177/0300060520973092] [PMID: 34488484]
[28]
Chen H, Zhou J, Chen Q, Deng Y. Comparison of the sensitivity of mammography, ultrasound, magnetic resonance imaging and combinations of these imaging modalities for the detection of small (≤2 cm) breast cancer. Medicine 2021; 100(26): e26531.
[http://dx.doi.org/10.1097/MD.0000000000026531] [PMID: 34190189]
[29]
Endrikat J, Schmidt G, Haverstock D, Weber O, Trnkova ZJ, Barkhausen J. Sensitivity of Contrast-Enhanced Breast MRI vs X-ray Mammography Based on Cancer Histology, Tumor Grading, Receptor Status, and Molecular Subtype: A Supplemental Analysis of 2 Large Phase III Studies. Breast Cancer (Auckl) 2022; 16: 11782234221092155.
[http://dx.doi.org/10.1177/11782234221092155] [PMID: 35462754]
[30]
Jakubowicz J, Heinze-Paluchowska S, Hendrick E, et al. Comparison between breast MRI and contrast-enhanced spectral mammography. Med Sci Monit 2015; 21: 1358-67.
[http://dx.doi.org/10.12659/MSM.893018] [PMID: 25963880]
[31]
DeMartini W, Lehman C, Partridge S. Breast MRI for cancer detection and characterization: A review of evidence-based clinical applications. Acad Radiol 2008; 15(4): 408-16.
[http://dx.doi.org/10.1016/j.acra.2007.11.006] [PMID: 18342764]
[32]
Lorenzetti DL, Ghali WA. Reference management software for systematic reviews and meta-analyses: An exploration of usage and usability. BMC Med Res Methodol 2013; 13(1): 141.
[http://dx.doi.org/10.1186/1471-2288-13-141] [PMID: 24237877]
[33]
Hanneman SK. Design, analysis, and interpretation of method-comparison studies. AACN Adv Crit Care 2008; 19(2): 223-34.
[http://dx.doi.org/10.1097/01.AACN.0000318125.41512.a3] [PMID: 18560291]
[34]
Sterne JAC, Becker BJ, Egger M. The funnel plot. In: Rothstein HR, Sutton AJ, Bornstein M, Eds. Publication bias in meta-analysis: prevention, assessment and adjustments. WWiley: West Sussex 2006; pp. 73-98.
[http://dx.doi.org/10.1002/0470870168.ch5]
[35]
Hanschmann H, Gärtner S, Berger R. Comparability of computer-supported concurrent voice analysis. Folia Phoniatr Logop 2015; 67(1): 8-14.
[http://dx.doi.org/10.1159/000381094] [PMID: 25925740]
[36]
Scully OJ, Bay BH, Yip G, Yu Y. Breast cancer metastasis. Cancer Genomics Proteomics 2012; 9(5): 311-20.
[PMID: 22990110]
[37]
Calle EE, Martin LM, Thun MJ, Miracle HL, Heath CW Jr. Family history, age, and risk of fatal breast cancer. Am J Epidemiol 1993; 138(9): 675-81.
[http://dx.doi.org/10.1093/oxfordjournals.aje.a116904] [PMID: 8237982]
[38]
Morris EA. Breast cancer imaging with MRI. Radiol Clin North Am 2002; 40(3): 443-66.
[http://dx.doi.org/10.1016/S0033-8389(01)00005-7] [PMID: 12117186]
[39]
Karellas A, Vedantham S. Breast cancer imaging: A perspective for the next decade. Med Phys 2008; 35(11): 4878-97.
[http://dx.doi.org/10.1118/1.2986144] [PMID: 19070222]
[40]
Houssami N, Ciatto S. The evolving role of new imaging methods in breast screening. Prev Med 2011; 53(3): 123-6.
[http://dx.doi.org/10.1016/j.ypmed.2011.05.003] [PMID: 21605590]
[41]
Turnbull LW. Dynamic contrast-enhanced MRI in the diagnosis and management of breast cancer. NMR Biomed 2009; 22(1): 28-39.
[http://dx.doi.org/10.1002/nbm.1273] [PMID: 18654999]
[42]
Mann RM, Kuhl CK, Moy L. Contrast‐enhanced MRI for breast cancer screening. J Magn Reson Imaging 2019; 50(2): 377-90.
[http://dx.doi.org/10.1002/jmri.26654] [PMID: 30659696]
[43]
Fischer U, Kopka L, Grabbe E. Breast carcinoma: Effect of preoperative contrast-enhanced MR imaging on the therapeutic approach. Radiology 1999; 213(3): 881-8.
[http://dx.doi.org/10.1148/radiology.213.3.r99dc01881] [PMID: 10580970]
[44]
Lehman CD, Schnall MD. Imaging in breast cancer: Magnetic resonance imaging. Breast Cancer Res 2005; 7(5): 215-9.
[http://dx.doi.org/10.1186/bcr1309] [PMID: 16168141]
[45]
Menezes GL, Knuttel FM, Stehouwer BL, Pijnappel RM, van den Bosch MA. Magnetic resonance imaging in breast cancer: A literature review and future perspectives. World J Clin Oncol 2014; 5(2): 61-70.
[http://dx.doi.org/10.5306/wjco.v5.i2.61]
[46]
Machida Y, Shimauchi A, Kanemaki Y, Igarashi T, Harada M, Fukuma E. Feasibility and potential limitations of abbreviated breast MRI: An observer study using an enriched cohort. Breast Cancer 2017; 24(3): 411-9.
[http://dx.doi.org/10.1007/s12282-016-0718-z] [PMID: 27485755]
[47]
Leithner D, Moy L, Morris EA, Marino MA, Helbich TH, Pinker K. Abbreviated MRI of the breast: Does it provide value. J Magn Reson Imaging 2019; 49(7): e85-e100.
[http://dx.doi.org/10.1002/jmri.26291] [PMID: 30194749]
[48]
Padia SA, Freyvogel M, Dietz J, Valente S, O’Rourke C, Grobmyer SR. False-positive extra-mammary findings in breast MRI: Another cause for concern. Breast J 2016; 22(1): 90-5.
[http://dx.doi.org/10.1111/tbj.12524] [PMID: 26511429]
[49]
Warner E. Screening BRCA1 and BRCA2 mutation carriers for breast cancer. Cancers 2018; 10(12): 477.
[http://dx.doi.org/10.3390/cancers10120477] [PMID: 30513626]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy